PMID: 9164424Apr 1, 1997Paper

A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients

The Journal of Clinical Psychiatry
A Kiev, A Feiger

Abstract

Fluvoxamine and paroxetine, both serotonin selective reuptake inhibitors (SSRIs), were compared at two centers in a 7-week double-blind study in outpatients with major depression, diagnosed by DSM-III-R criteria. Sixty patients were randomly assigned to receive dosage titrated upward to between 50-150 mg/day of fluvoxamine (N = 30) or 20-50 mg/day of paroxetine (N = 30). The mean +/- SD daily dose administered at the last assessment was 102 +/- 44 mg/day for fluvoxamine and 36 +/- 13 mg/day for paroxetine. Sixteen (53%) fluvoxamine-treated patients and 10 (33%) paroxetine-treated patients were titrated to the maximum permissible dosage of either drug. Sample size was calculated to provide at least 85% power at 5% level of significance to detect at least a 1.00-point difference in mean severity of adverse events, assuming a standard deviation of 1.0. Fluvoxamine and paroxetine were similarly effective in ameliorating depression as demonstrated by mean total scores of 10.9 +/- 7.3 (p < .00) and 11.5 +/- 7.4 (p < .00), respectively, in the Hamilton Rating Scale for Depression (HAM-D). Adverse events were mostly mild to moderate in severity. The most common events were headache (N = 17, 57%), nausea (N = 14, 47%), sweating (N = 10,...Continue Reading

Citations

Nov 8, 2006·Archives of General Psychiatry·Matthew J TaylorZubin Bhagwagar
Dec 3, 2005·Journal of Gastroenterology·Mariko HojoNobuhiro Sato
Jul 10, 2002·Journal of Affective Disorders·S A MontgomeryA Riley
Dec 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Juan Undurraga, Ross J Baldessarini
Nov 16, 2007·BioPsychoSocial Medicine·Takakazu OkaSadatoshi Tsuji
Dec 18, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Ursula ReichenpfaderBradley N Gaynes
Jun 27, 2012·International Journal of Psychiatry in Clinical Practice·Ali GhaleihaNasrin Matinnia
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S Mace, D Taylor
Dec 14, 2006·Expert Opinion on Pharmacotherapy·Paul J Goodnick
Jan 1, 2004·International Journal of Psychiatry in Clinical Practice·Stephen M Stahl
Sep 2, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gerald GartlehnerKathleen N Lohr
May 31, 2011·The Urologic Clinics of North America·Michael A Perelman
Aug 19, 2003·Human Psychopharmacology·Shigeru Morishita, Seizaburo Arita
Mar 6, 2004·Bipolar Disorders·Benjamin J D H Chun, David L Dunner
Jul 15, 2003·Human Psychopharmacology·Jean Dalery, Adriaan Honig
Oct 18, 2005·Human Psychopharmacology·Andrew G Mayers, David S Baldwin
Aug 18, 2016·Sexual Medicine Reviews·Daniel J SadowskiTobias S Köhler
May 28, 2015·Andrology·M J ButcherT S Köhler
Sep 1, 2002·Expert Review of Neurotherapeutics·Carlos E Fardella, Sergio Gloger
Sep 24, 2002·The Annals of Pharmacotherapy·Razmic S GregorianZeba M Khan
Sep 25, 2001·Depression and Anxiety·A WinokurM P Szuba
Oct 31, 2002·Human Psychopharmacology·Johan A. Den BoerBernhard R. Slaap
Nov 14, 2007·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Joel R SneedSteven P Roose
Feb 25, 2005·The Annals of Pharmacotherapy·Todd R Marcy, Mark L Britton
Mar 1, 2008·Journal of Psychopharmacology·K Demyttenaere, L Jaspers
May 1, 2008·Journal of the American Psychiatric Nurses Association·Barbara E WolfeAdrian T Smith
Feb 11, 2004·The Journal of Nervous and Mental Disease·Mark ZimmermanMichael A Posternak
Nov 27, 2001·British Medical Bulletin·D S Baldwin
Jan 8, 2004·Journal of Clinical Psychopharmacology·Herman G M WestenbergLuigi M Barbato
Nov 28, 2002·Journal of Clinical Psychopharmacology·Mark ZimmermanIwona Chelminski
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Ichiro M OmoriToshi A Furukawa
Apr 4, 2014·The Cochrane Database of Systematic Reviews·Marianna PurgatoCorrado Barbui
Apr 7, 2005·International Clinical Psychopharmacology·Masaki KatoToshihiko Kinoshita
Oct 3, 2002·The Journal of Nervous and Mental Disease·Daniel J Safer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.